Targeted Protein Degradation Market Size, Share & Trends Analysis Report By Type (PROTAC, Molecular Glues), By Application (Drug Discovery, Therapy Development), By End-use, By Region, And Segment Forecasts, 2025 - 2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,950	120 Pages	Grand View Research	January, 2025	GV19584306

Best Price Guarantee
Price	from $5,950
Length	120 Pages
Publisher	Grand View Research
Published Date	January, 2025
SKU	GV19584306

Table of Contents
Description

Targeted Protein Degradation Market Trends

The global targeted protein degradation market size was estimated at USD 544.4 million in 2024 and is projected to grow at a CAGR of 20.80% from 2025 to 2030. The constantly growing frequency of chronic disease conditions such as cancer and neurodegenerative diseases, along with changing lifestyles and increasing healthcare spending, are accelerating the market growth. The high prevalence of these diseases creates a strong demand for novel treatment options, driving market growth.

For instance, data from the World Health Organization (WHO) indicates that in 2022, around 20 million individuals were newly diagnosed with cancer, and there were 9.7 million cancer-related deaths. It's estimated that 53.5 million people were living with cancer within five years after receiving their diagnosis.

The expanding number of research and development activities in this field provides significant market growth opportunities. For instance, in December 2023, the Austrian Science Fund (FWF) approved the Special Research Program (SFB) in Targeted Protein Degradation for a second funding period of another four years. The SFB in Targeted protein degradation is a research initiative focusing on understanding and developing methods to target specific proteins for cell degradation. This program aims to advance the field of targeted protein degradation, which has gained significant attention in recent years due to its potential applications in drug discovery and therapeutic interventions.

The supportive regulatory environment, particularly the streamlined approval processes by agencies such as the FDA and EMA, has played a crucial role in accelerating the adoption of TPD-based therapies. Rapid advancements in the underlying technologies drive the targeted protein degradation industry. The development of innovative approaches, such as proteolysis-targeting chimeras (PROTACs), molecular glues, and lysosome-targeting chimeras (LYTACs), has expanded TPD's capabilities to eliminate disease-causing proteins selectively. These technological breakthroughs have opened up new avenues for targeting previously undruggable proteins, driving the growth of the targeted protein degradation industry.

The increasing recognition of the therapeutic potential of targeted protein degradation in addressing previously undruggable targets is a key driver for the targeted protein degradation industry. Traditional approaches often struggle with proteins that are difficult to modulate, but technologies such as PROTACs (proteolysis-targeting chimeras) provide a favorable solution by promoting the degradation of disease-causing proteins. This method has shown considerable promise in treating conditions such as cancer and neurodegenerative disorders, sparking a surge in research and investment in this area. The National Institute of Health highlights PROTACs as a leading drug development technology in recent years. The increasing success in preclinical and early-phase clinical trials drives pharmaceutical and biotech companies to integrate targeted protein degradation into their pipelines, recognizing its potential to transform therapeutic strategies.

Global Targeted Protein Degradation Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global targeted protein degradation market report based on type, application, end-use, and region.

Type Outlook (Revenue, USD Million, 2018 - 2030)
PROTAC
Molecular Glues
LYTACs
Others
Application Outlook (Revenue, USD Million, 2018 - 2030)
Drug Discovery
Therapy Development

Cancer

Neurology

Infectious Diseases

Cardiovascular Diseases

Others

End Use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Hospitals & Clinical Laboratories
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

China

Japan

India

South Korea

Australia

Thailand

Latin America

Brazil

Argentina

South Africa

Saudi Arabia

UAE

Kuwait

Please note The report will be delivered in 2-3 business days upon order notification.

Chapter 1. Methodology and Scope: 1.1. Market Segmentation & Scope; 1.2. Market Definitions; 1.2.1. Type Segment; 1.2.2. Application Segment; 1.2.3. End Use Segment; 1.3. Information analysis; 1.3.1. Market formulation & data visualization; 1.4. Data validation & publishing; 1.5. Information Procurement; 1.5.1. Primary Research; 1.6. Information or Data Analysis; 1.7. Market Formulation & Validation; 1.8. Market Model; 1.9. Total Market: CAGR Calculation; 1.10. Objectives
Chapter 2. Executive Summary: 2.1. Market Outlook; 2.2. Segment Snapshot; 2.3. Competitive Landscape Snapshot
Chapter 3. Targeted Protein Degradation Market Variables & Trends: 3.1. Market Lineage Outlook; 3.1.1. Parent market outlook; 3.1.2. Related/ancillary market outlook.; 3.2. Market Dynamics; 3.2.1. Market driver analysis; 3.2.1.1. Growing frequency of chronic diseases; 3.2.1.2. Research and development activities; 3.2.1.3. Increasing recognition of the therapeutic potential of targeted protein degradation; 3.2.2. Market restraint analysis; 3.2.2.1. High cost; 3.2.2.2. Stringent regulations associated with approvals for novel TPD based therapies; 3.3. Targeted Protein Degradation Market Analysis Tools; 3.3.1. Industry Analysis - Porter’s; 3.3.2. PESTEL Analysis; 3.3.3. COVID-19 Impact Analysis
Chapter 4. Targeted Protein Degradation Market: Type Estimates & Trend Analysis: 4.1. Segment Dashboard; 4.2. Global Targeted Protein Degradation Market Type Movement Analysis; 4.3. Global Targeted Protein Degradation Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million); 4.4. PROTAC; 4.4.1. PROTAC market estimates and forecasts 2018 to 2030 (USD Million); 4.5. Molecular Glues; 4.5.1. Molecular Glues market estimates and forecasts 2018 to 2030 (USD Million); 4.6. LYTACs; 4.6.1. LYTACs market estimates and forecasts 2018 to 2030 (USD Million); 4.7. Others; 4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Targeted Protein Degradation Market: Application Estimates & Trend Analysis: 5.1. Segment Dashboard; 5.2. Global Targeted Protein Degradation Market Application Movement Analysis; 5.3. Global Targeted Protein Degradation Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million); 5.4. Drug Discovery; 5.4.1. Drug Discovery market estimates and forecasts 2018 to 2030 (USD Million); 5.5. Therapy Development; 5.5.1. Therapy Development market estimates and forecasts 2018 to 2030 (USD Million); 5.5.2. Cancer; 5.5.2.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million); 5.5.3. Neurology; 5.5.3.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million); 5.5.4. Infectious Diseases; 5.5.4.1. Infectious Diseases market estimates and forecasts 2018 to 2030 (USD Million); 5.5.5. Cardiovascular Diseases; 5.5.5.1. Cardiovascular Diseases market estimates and forecasts 2018 to 2030 (USD Million); 5.5.6. Others; 5.5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Targeted Protein Degradation Market: End Use Estimates & Trend Analysis: 6.1. Segment Dashboard; 6.2. Global Targeted Protein Degradation Market End Use Movement Analysis; 6.3. Global Targeted Protein Degradation Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million); 6.4. Pharmaceutical & Biotechnology Companies; 6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million); 6.5. Academic & Research Institutes; 6.5.1. Academic & Research Institutes market estimates and forecasts 2018 to 2030 (USD Million); 6.6. Hospitals & Clinical Laboratories; 6.6.1. Hospitals & Clinical Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Targeted Protein Degradation Market: Regional Estimates & Trend Analysis: 7.1. Regional Market Share Analysis, 2024 & 2030; 7.2. Regional Market Dashboard; 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:; 7.4. North America; 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million); 7.4.2. U.S.; 7.4.2.1. Key country dynamics; 7.4.2.2. Competitive scenario; 7.4.2.3. Regulatory framework; 7.4.2.4. Target disease prevalence; 7.4.2.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million); 7.4.3. Canada; 7.4.3.1. Key country dynamics; 7.4.3.2. Competitive scenario; 7.4.3.3. Regulatory framework; 7.4.3.4. Target disease prevalence; 7.4.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million); 7.4.4. Mexico; 7.4.4.1. Key country dynamics; 7.4.4.2. Competitive scenario; 7.4.4.3. Regulatory framework; 7.4.4.4. Target disease prevalence; 7.4.4.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million); 7.5. Europe; 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million); 7.5.2. UK; 7.5.2.1. Key country dynamics; 7.5.2.2. Competitive scenario; 7.5.2.3. Regulatory framework; 7.5.2.4. Target disease prevalence; 7.5.2.5. UK market estimates and forecasts 2018 to 2030 (USD Million); 7.5.3. Germany; 7.5.3.1. Key country dynamics; 7.5.3.2. Competitive scenario; 7.5.3.3. Regulatory framework; 7.5.3.4. Target disease prevalence; 7.5.3.5. Germany market estimates and forecasts 2018 to 2030 (USD Million); 7.5.4. France; 7.5.4.1. Key country dynamics; 7.5.4.2. Competitive scenario; 7.5.4.3. Regulatory framework; 7.5.4.4. Target disease prevalence; 7.5.4.5. France market estimates and forecasts 2018 to 2030 (USD Million); 7.5.5. Italy; 7.5.5.1. Key country dynamics; 7.5.5.2. Competitive scenario; 7.5.5.3. Regulatory framework; 7.5.5.4. Target disease prevalence; 7.5.5.5. Italy market estimates and forecasts 2018 to 2030 (USD Million); 7.5.6. Spain; 7.5.6.1. Key country dynamics; 7.5.6.2. Competitive scenario; 7.5.6.3. Regulatory framework; 7.5.6.4. Target disease prevalence; 7.5.6.5. Spain market estimates and forecasts 2018 to 2030 (USD Million); 7.5.7. Norway; 7.5.7.1. Key country dynamics; 7.5.7.2. Competitive scenario; 7.5.7.3. Regulatory framework; 7.5.7.4. Target disease prevalence; 7.5.7.5. Norway market estimates and forecasts 2018 to 2030 (USD Million); 7.5.8. Sweden; 7.5.8.1. Key country dynamics; 7.5.8.2. Competitive scenario; 7.5.8.3. Regulatory framework; 7.5.8.4. Target disease prevalence; 7.5.8.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million); 7.5.9. Denmark; 7.5.9.1. Key country dynamics; 7.5.9.2. Competitive scenario; 7.5.9.3. Regulatory framework; 7.5.9.4. Target disease prevalence; 7.5.9.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million); 7.6. Asia Pacific; 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million); 7.6.2. Japan; 7.6.2.1. Key country dynamics; 7.6.2.2. Competitive scenario; 7.6.2.3. Regulatory framework; 7.6.2.4. Target disease prevalence; 7.6.2.5. Japan market estimates and forecasts 2018 to 2030 (USD Million); 7.6.3. China; 7.6.3.1. Key country dynamics; 7.6.3.2. Competitive scenario; 7.6.3.3. Regulatory framework; 7.6.3.4. Target disease prevalence; 7.6.3.5. China market estimates and forecasts 2018 to 2030 (USD Million); 7.6.4. India; 7.6.4.1. Key country dynamics; 7.6.4.2. Competitive scenario; 7.6.4.3. Regulatory framework; 7.6.4.4. Target disease prevalence; 7.6.4.5. India market estimates and forecasts 2018 to 2030 (USD Million); 7.6.5. Australia; 7.6.5.1. Key country dynamics; 7.6.5.2. Competitive scenario; 7.6.5.3. Regulatory framework; 7.6.5.4. Target disease prevalence; 7.6.5.5. Australia market estimates and forecasts 2018 to 2030 (USD Million); 7.6.6. South Korea; 7.6.6.1. Key country dynamics; 7.6.6.2. Competitive scenario; 7.6.6.3. Regulatory framework; 7.6.6.4. Target disease prevalence; 7.6.6.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million); 7.6.7. Thailand; 7.6.7.1. Key country dynamics; 7.6.7.2. Competitive scenario; 7.6.7.3. Target disease prevalence; 7.6.7.4. Regulatory framework; 7.6.7.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million); 7.7. Latin America; 7.7.1. Market estimates and forecasts 2018 to 2030 (USD Million); 7.7.2. Brazil; 7.7.2.1. Key country dynamics; 7.7.2.2. Competitive scenario; 7.7.2.3. Regulatory framework; 7.7.2.4. Target disease prevalence; 7.7.2.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million); 7.7.3. Argentina; 7.7.3.1. Key country dynamics; 7.7.3.2. Competitive scenario; 7.7.3.3. Regulatory framework; 7.7.3.4. Target disease prevalence; 7.7.3.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million); 7.8. MEA; 7.8.1. Market estimates and forecasts 2018 to 2030 (USD Million); 7.8.2. South Africa; 7.8.2.1. Key country dynamics; 7.8.2.2. Competitive scenario; 7.8.2.3. Regulatory framework; 7.8.2.4. Target disease prevalence; 7.8.2.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million); 7.8.3. Saudi Arabia; 7.8.3.1. Key country dynamics; 7.8.3.2. Competitive scenario; 7.8.3.3. Regulatory framework; 7.8.3.4. Target disease prevalence; 7.8.3.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million); 7.8.4. UAE; 7.8.4.1. Key country dynamics; 7.8.4.2. Competitive scenario; 7.8.4.3. Regulatory framework; 7.8.4.4. Target disease prevalence; 7.8.4.5. UAE market estimates and forecasts 2018 to 2030 (USD Million); 7.8.5. Kuwait; 7.8.5.1. Key country dynamics; 7.8.5.2. Competitive scenario; 7.8.5.3. Regulatory framework; 7.8.5.4. Target disease prevalence; 7.8.5.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape: 8.1. Company/Competition Categorization; 8.2. Strategy Mapping; 8.3. Company Market Position Analysis, 2024; 8.4. Company Profiles/Listing; 8.4.1. Bayer AG; 8.4.1.1. Company overview; 8.4.1.2. Financial performance; 8.4.1.3. Type benchmarking; 8.4.1.4. Strategic initiatives; 8.4.2. Bio-Techne; 8.4.2.1. Company overview; 8.4.2.2. Financial performance; 8.4.2.3. Type benchmarking; 8.4.2.4. Strategic initiatives; 8.4.3. BOC Sciences; 8.4.3.1. Company overview; 8.4.3.2. Financial performance; 8.4.3.3. Type benchmarking; 8.4.3.4. Strategic initiatives; 8.4.4. BPS Bioscience, Inc.; 8.4.4.1. Company overview; 8.4.4.2. Financial performance; 8.4.4.3. Type benchmarking; 8.4.4.4. Strategic initiatives; 8.4.5. BroadPharm; 8.4.5.1. Company overview; 8.4.5.2. Financial performance; 8.4.5.3. Type benchmarking; 8.4.5.4. Strategic initiatives; 8.4.6. LifeSensors Inc.; 8.4.6.1. Company overview; 8.4.6.2. Financial performance; 8.4.6.3. Type benchmarking; 8.4.6.4. Strategic initiatives; 8.4.7. MedChemExpress.; 8.4.7.1. Company overview; 8.4.7.2. Financial performance; 8.4.7.3. Type benchmarking; 8.4.7.4. Strategic initiatives; 8.4.8. Merck KGaA; 8.4.8.1. Company overview; 8.4.8.2. Financial performance; 8.4.8.3. Type benchmarking; 8.4.8.4. Strategic initiatives; 8.4.9. Promega Corporation; 8.4.9.1. Company overview; 8.4.9.2. Financial performance; 8.4.9.3. Type benchmarking; 8.4.9.4. Strategic initiatives; 8.4.10. Thermo Fisher Scientific, Inc.; 8.4.10.1. Company overview; 8.4.10.2. Financial performance; 8.4.10.3. Type benchmarking; 8.4.10.4. Strategic initiatives